539805Ar1.qxd:Layout 1 11/7/08 10:48 AM Page 1 Giving Opportunities Name Gift Atrium Promenade $5 million Beyond The Phlebotomy Treatment Center $5 million Extraordinary 3-Level Parking Garage $5 million Auditorium $5 million Family Education Center $5 million Grand Concourse/Waiting Area $2 million Dining Room (48 seats) $2 million Diagnostic Laboratory Suite $2 million Administration Wing $1 million Resource Library $1 million Conference Suite (18 seats) $1 million Conference Wing (4 rooms) $1 million Retail Pharmacy $1 million Food Preparation Instruction Area $500,000 Chairman’s Office Suite $500,000 Tranquility Room $500,000 Hackensack University Medical Center Foundation 360 Essex Street, Suite 301, Hackensack, NJ 07601-8566 www.humcfoundation.com 539805Ar1.qxd:Layout 1 11/7/08 10:48 AM Page 1 Giving Opportunities Name Gift Atrium Promenade $5 million Beyond The Phlebotomy Treatment Center $5 million Extraordinary 3-Level Parking Garage $5 million Auditorium $5 million Family Education Center $5 million Grand Concourse/Waiting Area $2 million Dining Room (48 seats) $2 million Diagnostic Laboratory Suite $2 million Administration Wing $1 million Resource Library $1 million Conference Suite (18 seats) $1 million Conference Wing (4 rooms) $1 million Retail Pharmacy $1 million Food Preparation Instruction Area $500,000 Chairman’s Office Suite $500,000 Tranquility Room $500,000 Hackensack University Medical Center Foundation 360 Essex Street, Suite 301, Hackensack, NJ 07601-8566 www.humcfoundation.com Atrium Promenade atients will be welcomed to the new John Theurer Cancer Left to right Center via the Atrium Promenade, an airy and inviting space offering easy access to all the services they need. Here they Andrew Pecora, M.D. P Chairman & Executive Administrative will confirm appointments, complete paperwork, and have tests Director, the John Theurer Cancer Center and blood work done. Everything will be designed to ensure that Elizabeth Koller, R.N. patients know where to go and when, and how to get there. Administrative Director, First-time visitors will be introduced to all the resources and the John Theurer Cancer Center facilities within the center. The administrative staff is currently André Goy, M.D., M.S. developing a system that will help guide the patient through the Deputy Director, the John Theurer building. Like personal shoppers, ‘patient navigators’ will assess Cancer Center; the unique needs of each person and pinpoint the services most Chief, Division of Lymphoma Oncology; and Director of Cancer Research likely to benefit him or her. From this floor, administrators will manage all cancer center Dan Smith, M.D. operations, including strategic planning, budget management, Chief, Division of Gynecologic Oncology and Vice Chairman, the John Theurer supervision of the nursing staff, and job training for employees. Cancer Center Through their ongoing negotiations with Medicare and other health insurance providers, they will also ensure that our patients receive extraordinary care at the best possible value. Page One Research and Clinical Trials reat medical centers have great research programs, and HUMC is no exception. More than ever, we are putting GG the discoveries of our lab into the hands of our clinicians to improve outcomes for patients. We work jointly with the National Cancer Institute to develop innovative treatments for a variety of cancers, and our continuing research in stem cell transplantation and immunotherapy has helped to save many lives while earning us a worldwide reputation in this field. Essential to our success is the dynamic intellectual exchange between scientists and medical oncologists–interaction that the new John Theurer Cancer Center will serve to enhance. By centralizing our operations, we will afford our research chief more opportunities to consult and share ideas with division chiefs and their staffs. Our research nurses and data coordinators–who collect and manage information for new pharmaceutical trials–will no longer be housed apart from their colleagues, but will work in close proximity with them as key members of each division’s specialized team of experts. This bench-to-bedside collaboration between lab and treatment teams should also help to increase patient participation in clinical trials. More than half our patients are eligible for the more than 75 trials we’re now conducting. Of those patients, three-quarters are enrolled–a record that surpasses the performance of many of the finest hospitals. Our investment in research and clinical trials is the surest path to greater personalized care, cancer prevention, and cure. Page Two Robert Korngold, Ph.D. André Goy, M.D., M.S. Chairman of the Department of Research Deputy Director, the John Theurer Cancer Center; Hackensack University Medical Center Chief, Division of Lymphoma Oncology; and Director of Cancer Research Dr. Korngold leads the research “Research is the key to our future, Dr. Goy’s research centers on division at HUMC, where and we’re becoming a national developing biomarkers for scientists are investigating both novel and conventional ways to improve prevention leader in this area. I work with the therapies in lymphoma as a and treatment of disease. clinicians on their own research model. As Deputy Director of His specialty is adult blood goals, and the new cancer center the John Theurer Cancer and marrow stem cell will facilitate that interaction. Center, Dr. Goy is responsible transplantation. There are many diseases we don’t for clinical and translational Dr. Korngold has devoted yet understand. We have a lot of cancer research at HUMC, his career to refining the stem with the goal of integrating cell transplantation process potential treatments waiting in these biomarkers across all and studying the mechanisms the wings. An immunotherapeutic divisions of the cancer center of graft-versus-host disease, a approach can save lives, and to hopefully design more potentially fatal side effect of that’s what we’re after.” molecularly relevant clinical stem cell transplantation that trials in the future. Dr. Korngold occurs when donor cells stage an immune response to “Thanks to the progress of organs in the patient’s body technology as well as the human and attack them. genome sequencing, we can now characterize the tumors from the molecular standpoint. A tumor’s behavior, its aggressiveness, sensitivity or resistance to chemotherapy, is dependent on the sum of the molecular defects accumulated within the tumor cells over time.” Dr. Goy Page Three Thea M. Friedman, Ph.D. K. Stephen Suh, Ph.D. Director of Research Laboratory Services Laboratory Director Tumor Bank and Genomics Program Dr. Friedman directs basic “I always knew that basic Dr. Suh’s research at the research at the cancer center research would be my calling, Tumor Bank laboratory focuses laboratory, where scientists are and the clinicians here are on science to identify molecular looking for ways to prevent or markers (biomarkers) for cure cancer by studying the staunch supporters of our multiple human cancers. mechanisms of the disease. research. We help each other in Biomarker discovery projects She specializes in the field of whatever ways we can. They are designed specifically for blood and marrow stem cell take time out of their incredibly each cancer type, and the transplantation. overburdened schedules to laboratory is currently working Dr. Friedman’s research has on lymphoma and ovarian concentrated on reducing the engage in intellectual exchange cancer projects. The laboratory incidence and severity of with us.” Dr. Friedman has set up the world’s largest graft-versus-host disease, which collection of cancer cell lines occurs when some of the donated, for mantle cell lymphoma and disease-fighting T-cells recognize “For the past 15 years, scientists ovarian cancer to be used in the patient’s organs as foreign have spent billions of dollars in an research. The Tumor Bank objects and attack them. Using unsuccessful search for a cancer program is also developing a molecular finger printing innovative methods for tissue technology, Dr. Friedman can biomarker, failing because some of procurement to collect cancer distinguish those ‘bad’ T-cells their cancer samples were junk- specimens with the highest from the ‘good’ ones, which quality. In our research, we use quality. attack the malignancy instead. only the finest specimens. So I’m Her goal is to enhance the confident we’ll achieve major ability of the ‘good’ cells to combat leukemia, myeloma, breakthroughs in biomarker and other cancers. The research discovery at our new cancer grants she has received in this center.” Dr. Suh field are among the most prestigious awarded by the National Institutes of Health. Page Four Jonathan Walland, LL.B., M.B.A. Richard Rosenbluth, M.D. Director of Clinical Research Chief, Division of Geriatric Oncology Jonathan Walland leads the “Cancer risk increases with Dr. Rosenbluth, a hematologist clinical research program at age, and by 2030, a fifth of the and oncologist, has been on the cancer center, which offers population will be 65+. Elderly the medical staff at HUMC patients access to over 75 for more than 30 years and is experimental cancer patients who are vulnerable medical director of HUMC’s therapies. Working with a and frail need special assessment hospice program. He was multidisciplinary team of more and the multidisciplinary recently chosen to head the than 50 research nurses, approach in which we specialize. cancer center’s new geriatric research